budesonide NDC 72162-2473

NDC codes

FDA NDC Directory

Product NDC (as listed)72162-2473Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72162-2473Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72162-2473-1	72162247301	1 BOTTLE in 1 CARTON (72162-2473-1) / 100 CAPSULE in 1 BOTTLEMarketed from Apr 24, 2025
72162-2473-2	72162247302	1 BOTTLE in 1 CARTON (72162-2473-2) / 100 CAPSULE in 1 BOTTLEMarketed from Apr 24, 2025

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): budesonide
Generic name (nonproprietary): budesonide
Active ingredients: Budesonide — 3 mg/1
Dosage form: Capsule
Route: Oral
Labeler: Bryant Ranch Prepack
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 021324
Marketing start: Jun 29, 2018
Listing expires: Dec 31, 2027
Other FDA classes: Corticosteroid Hormone Receptor Agonists (Mechanism)
Identifiers: Product ID 72162-2473_53dbaeb6-8bff-46dc-afb8-1c6581bb24ebSPL ID 53dbaeb6-8bff-46dc-afb8-1c6581bb24ebSPL set ID 33def4dc-b469-f987-e063-6294a90ace0bRxCUI 1244214UNII Q3OKS62Q6X
Pharmacologic class: Corticosteroid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472162247301 followed by a unit qualifier and the quantity

Package 72162-2473-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 17, 2026.

Indications (excerpt from the label)

Budesonide delayed-release capsules are a corticosteroid indicated for: Treatment of mild to moderate active Crohn’s disease involving the ileum and/or the ascending colon, in patients 8 years and older. ( 1.1 ) Maintenance of clinical remission of mild to moderate Crohn’s disease involving the ileum and/or the ascending colon for up to 3 months in adults. ( 1.2 ) 1.1 Treatment of Mild to Moderate Active Crohn’s Disease Budesonide delayed-release capsules are indicated for the treatment of mild to moderate active Crohn's disease involving the ileum and/or the ascending colon in patients 8 years of age and older. 1.2 Maintenance of Clinical Remission of Mild to Moderate Crohn’s Disease Budeso…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 021324

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 021324
Product	Strength	Form · route	Labeler	Product NDC
budesonide	Budesonide 3 mg/1	CapsuleOral	Padagis US LLC	0574-9855
budesonide	Budesonide 3 mg/1	CapsuleOral	Golden State Medical Supply, Inc.	51407-591